Compare CXM & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXM | CERT |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 978.7M |
| IPO Year | 2021 | 2020 |
| Metric | CXM | CERT |
|---|---|---|
| Price | $6.05 | $5.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $8.31 | ★ $12.22 |
| AVG Volume (30 Days) | 2.5M | ★ 4.2M |
| Earning Date | 03-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $857,200,000.00 | $418,838,000.00 |
| Revenue This Year | $2.52 | $4.26 |
| Revenue Next Year | $4.94 | $5.40 |
| P/E Ratio | $66.44 | ★ N/A |
| Revenue Growth | 7.64 | ★ 8.75 |
| 52 Week Low | $5.12 | $5.39 |
| 52 Week High | $9.40 | $15.38 |
| Indicator | CXM | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 23.80 |
| Support Level | $5.64 | N/A |
| Resistance Level | $6.15 | $11.62 |
| Average True Range (ATR) | 0.22 | 0.30 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 75.76 | 8.95 |
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.